Combined anti-PD-1 and anti-CTLA-4 checkpoint blockade: Treatment of melanoma and immune mechanisms of action. (2021)
Attributed to:
Preclinical efficacy of an antibody of the IgE class against a melanoma-associated antigen
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1002/eji.202048747
PubMed Identifier: 33450785
Publication URI: http://europepmc.org/abstract/MED/33450785
Type: Journal Article/Review
Volume: 51
Parent Publication: European journal of immunology
Issue: 3
ISSN: 0014-2980